Piper Jaffray analyst William Quirk reiterated an Overweight rating and boosted his price target on Myriad Genetics (NASDAQ: MYGN) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains SidelinedNovember 4, 2015 7:57 AM Myriad Genetics (MYGN) PT Up to $46 at Leerink Partners After Solid Q1November 4, 2015 7:21 AM Myriad Genetics (MYGN) Tops Q1 EPS by 6cNovember 3, 2015 4:14 PM Myriad Genetics Reports Fiscal First-Quarter 2016 Financial ResultsNovember 3, 2015 4:06 PM